A61K 2039/51
Comprising whole cells, viruses or dna/rna
Official title: {comprising whole cells, viruses or DNA/RNA}
A61K2039/51 (Comprising whole cells, viruses or dna/rna) appears on 10,921 US grants and 17,086 published applications in this corpus.
Search patents in A61K- Granted patents
- 10,921
- Published applications
- 17,086
- Assignees
- 4,684
- Inventors
- 23,265
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 18 | 0 |
| 1977 | 19 | 0 |
| 1978 | 11 | 0 |
| 1979 | 7 | 0 |
| 1980 | 9 | 0 |
| 1981 | 14 | 0 |
| 1982 | 20 | 0 |
| 1983 | 4 | 0 |
| 1984 | 9 | 0 |
| 1985 | 22 | 0 |
| 1986 | 13 | 0 |
| 1987 | 24 | 0 |
| 1988 | 16 | 0 |
| 1989 | 14 | 0 |
| 1990 | 11 | 0 |
| 1991 | 22 | 0 |
| 1992 | 17 | 0 |
| 1993 | 15 | 0 |
| 1994 | 18 | 0 |
| 1995 | 30 | 0 |
| 1996 | 35 | 0 |
| 1997 | 76 | 0 |
| 1998 | 159 | 0 |
| 1999 | 177 | 0 |
| 2000 | 222 | 0 |
| 2001 | 223 | 56 |
| 2002 | 228 | 447 |
| 2003 | 238 | 645 |
| 2004 | 220 | 680 |
| 2005 | 203 | 622 |
| 2006 | 278 | 531 |
| 2007 | 268 | 540 |
| 2008 | 292 | 587 |
| 2009 | 323 | 620 |
| 2010 | 381 | 718 |
| 2011 | 393 | 672 |
| 2012 | 357 | 604 |
| 2013 | 338 | 542 |
| 2014 | 423 | 534 |
| 2015 | 390 | 581 |
| 2016 | 463 | 681 |
| 2017 | 490 | 722 |
| 2018 | 545 | 726 |
| 2019 | 564 | 795 |
| 2020 | 549 | 755 |
| 2021 | 550 | 826 |
| 2022 | 498 | 918 |
| 2023 | 474 | 943 |
| 2024 | 505 | 1000 |
| 2025 | 456 | 778 |
| 2026 | 290 | 563 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Lipid nanoparticles comprising sterols and mRNA6 Oct 2026US 12,751,999 B2eTheRNA Immunitherapies NV
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- NKG2A-targeting antibody and use thereof6 Oct 2026US 12,753,231 B2Bioheng Therapeutics Limited
- Use of E. coli strains expressing high level of α-Gal to modulate immunity and provide protection against infectious diseases in animals29 Sep 2026US 12,745,790 B2Biologicke Centrum AV CR v. v. i.
- Modular multiplatform system for mrna drug production8 Oct 2026US 2026/0306407 A1BioNTech SE
- Lipid nanoparticle for delivering nucleic acid drug, and preparation method therefor and use thereof8 Oct 2026US 2026/0306419 A1Cansino (Shanghai) Biological Research Co., Ltd.
- Antigen-specific physiologic dendritic cells for therapy8 Oct 2026US 2026/0306597 A1Emory University
- Sarcoma cancer vaccines and uses thereof8 Oct 2026US 2026/0306600 A1
- Lipid nanoparticles for the prevention of tuberculosis or other mycobacterial infections8 Oct 2026US 2026/0306603 A1Akagera Medicines, Inc.
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Methods for selectively stimulating proliferation of T cells341US 5,858,358 ADana-Farber Cancer Institute, Inc. · 1999
- CD9 antigen peptides and antibodies thereto326US 5,883,223 A1999